ORGANIC
LETTERS
2006
Vol. 8, No. 5
975-978
A Versatile Approach toward the
Ansamycin Antibiotics
Weimin Peng and Brian S. J. Blagg*
Department of Medicinal Chemistry and The Center for Chemical Methodology and
Library DeVelopment, The UniVersity of Kansas, 1251 Wescoe Hall DriVe,
Malott 4070, Lawrence, Kansas 66045-7562
Received January 4, 2006
ABSTRACT
The ansamycin antibiotics contain metacyclophanic macrolactams, many of which possess potent antitumor activity. Only a few total syntheses
of this family of natural products have been reported, and modifications to increase potency have not been described. Therefore, a method
was developed to prepare the trienomycin A core via resin-bound triphenylphosphonium salts, which serve as both a reagent and a traceless
linker to afford olefinic products that undergo ring-closing metathesis (RCM) to give macrocyclic scaffolds of varying ring sizes.
The ansamycin family of antibiotics consists of more than
20 members, many of which exhibit potent biological
activities such as geldanamycin, from which derivatives are
currently in clinical trials for the treatment of cancer (Figure
1).1,2 Another important member of this family is trienomycin
A, which like geldanamycin is also a macrolactam that
contains an oxygenated aromatic ring.3 Similar to geldana-
mycin, trienomycin A has exceptional activity against several
cancer cell lines4,5 and has been shown to cause a decrease
in nitric oxide synthase,6 suggesting that these molecules may
share a common biological target.7,8 Because the quinone
ring of GDA has demonstrated redox-active behavior,9 it has
been proposed that more stable derivatives are likely to serve
as important leads for clinical development.10 Trienomycin
A lacks the quinone moiety and instead contains a phenol,
which is not subject to the same redox-active behavior. The
ancillary ring of trienomycin A contains several function-
alities that differ from those of geldanamycin and perhaps
can be optimized for increased biological activity. Such
attributes make trienomycin A an excellent target for the
development of analogues and elucidation of its biological
target.
In an effort to provide synthetic access to members of the
ansamycin family, we sought to develop a versatile method
(1) Banerji, U. Proc. Am. Assoc. Cancer Res. 2003, 44, 677.
(2) Sausville, E. A. Curr. Cancer Drug Targets 2003, 3, 377-383.
(3) Funayama, S.; Okada, K.; Komiyama, K.; Umezawa, I. J. Antibiot.
1985, 38, 1107-1109.
(7) Garcia-Cardena, G.; Fan, R.; Shah, V.; Sorrentino, R.; Cirino, G.;
Papapetropoulos, A.; Sessa, W. C. Nature 1998, 392, 821-824.
(8) Pritchard, K. A.; Ackerman, A. W.; Gross, E. R.; Stepp, D. W.; Shi,
Y.; Fontana, J. T.; Baker, J. E.; Sessa, W. C. J. Biol. Chem. 2001, 276,
17621-17624.
(4) Komiyama, K.; Hirokawa, Y.; Yamaguchi, H.; Funayama, S.;
Masuda, K.; Anraku, Y.; Umezawa, I.; Omura, S. J. Antibiot. 1987, 40,
1768-1772.
(9) Dikalov, S.; Landmesser, U.; Harrison, D. G. J. Biol. Chem. 2002,
277, 25480-25485.
(5) Umezawa, I.; Funayama, S.; Okada, K.; Iwasaki, K.; Satoh, J.;
Masuda, K.; Komiyama, K. J. Antibiot. 1985, 38, 699-705.
(6) Kim, W.-G.; Song, N.-K.; Yoo, I.-D. J. Antibiot. 2002, 55, 204-
207.
(10) Patel, K.; Piagentini, M.; Rascher, A.; Tian, Z.-Q.; Buchanan, G.
O.; Regentin, R.; Hu, Z.; Hutchinson, C. R.; McDaniel, R. Chem. Biol.
2004, 11, 1625-1633.
10.1021/ol060022b CCC: $33.50
© 2006 American Chemical Society
Published on Web 02/04/2006